Merck KGaA, Darmstadt, Germany clinical trials

Part of E. Merck KG, which holds 70.274% as of 2025-12-31. Source

The registry lists 522 studies whose lead sponsor is Merck KGaA, Darmstadt, Germany or one of 4 companies grouped under it. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 522. Browse all 522 →

• Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)RecruitingNCT07499362Phase 2

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasNot yet recruitingNCT07850635Phase 1

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Phase 3

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsRecruitingNCT07360314Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibRecruitingNCT06997276Phase 1

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)RecruitingNCT07176689Phase 4

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy ParticipantsRecruitingNCT07840612Phase 1

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)RecruitingNCT07549412Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Anti-GD2 ADC M3554 in Advanced Solid TumorsRecruitingNCT06641908Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsRecruitingNCT07166601Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruitingNCT07332481Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)RecruitingNCT07355218Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Individual Patient Compassionate Use of MirdametinibAvailableNCT05028166

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Individual Patient Compassionate Use of NirogacestatAvailableNCT05041036

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Met Non Small Cell Cancer Registry (MOMENT)RecruitingNCT05376891

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• SW-682 in Advanced Solid TumorsRecruitingNCT06251310Phase 1

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Not yet recruitingNCT07840287Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)RecruitingNCT07340827Phase 3

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Phase 1/2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy ParticipantsSuspendedNCT06577337Phase 1

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active, not recruitingNCT05540327Phase 2

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruitingNCT03962543Phase 2

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Active, not recruitingNCT07170644Phase 2

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)CompletedNCT05396833Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of M5049 in DM and PM Participants (NEPTUNIA)TerminatedNCT05650567Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruitingNCT06421935Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Nirogacestat in Ovarian Granulosa Cell TumorsCompletedNCT05348356Phase 2

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedNCT03940703Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Mirdametinib + BGB-3245 in Advanced Solid TumorsTerminatedNCT05580770Phase 1/2

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)CompletedNCT03785964Phase 3

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Active, not recruitingNCT04170153Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment StudyCompletedNCT06412848

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsActive, not recruitingNCT06806046Phase 1

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)Active, not recruitingNCT05797740

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active, not recruitingNCT05464030Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)CompletedNCT04941768

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy ParticipantsCompletedNCT07279233Phase 1

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Evaluate the Effects of Famotidine or Rabeprazole on the PK of NirogacestatCompletedNCT07171619Phase 1

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• First in Human Study of M6223CompletedNCT04457778Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Effect of Renal Impairment on Enpatoran PharmacokineticsCompletedNCT06589713Phase 1

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male ParticipantsCompletedNCT07259330Phase 1

  Sponsor listed in the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)CompletedNCT06308263Phase 1

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

• First in Human Study of M1069 in Advanced Solid TumorsTerminatedNCT05198349Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian OriginCompletedNCT07269327Phase 1

  Sponsor listed in the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany